tradingkey.logo
tradingkey.logo
Search

ImageneBio Ord Shs

IMA
Add to Watchlist
3.470USD
+0.020+0.58%
Close 11-13 16:00(ET)
39.38MMarket Cap
LossP/E TTM

About ImageneBio Ord Shs Company

ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

ImageneBio Ord Shs Profile

Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -

Company Executives of ImageneBio Ord Shs

Name
Name/Position
Position
Shareholding
Change
Dr. Kristin Yarema, Ph.D.
Dr. Kristin Yarema, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
493.70K
+51.61%
Ms. Yanina Grant-Huerta
Ms. Yanina Grant-Huerta
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
104.00K
--
Ms. Erin Butler
Ms. Erin Butler
Senior Vice President - Finance, Administration
Senior Vice President - Finance, Administration
25.55K
+88.06%
Mr. Joseph P. (Joe) Slattery
Mr. Joseph P. (Joe) Slattery
Independent Director
Independent Director
16.00K
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Otello Stampacchia, Ph.D.
Dr. Otello Stampacchia, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Yufang Lu, M.D., Ph.D.
Dr. Yufang Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jian (Jonathan) Wang
Dr. Jian (Jonathan) Wang
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Matthew (Matt) Robbins
Mr. Matthew (Matt) Robbins
General Counsel
General Counsel
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Kristin Yarema, Ph.D.
Dr. Kristin Yarema, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
493.70K
+51.61%
Ms. Yanina Grant-Huerta
Ms. Yanina Grant-Huerta
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
104.00K
--
Ms. Erin Butler
Ms. Erin Butler
Senior Vice President - Finance, Administration
Senior Vice President - Finance, Administration
25.55K
+88.06%
Mr. Joseph P. (Joe) Slattery
Mr. Joseph P. (Joe) Slattery
Independent Director
Independent Director
16.00K
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Otello Stampacchia, Ph.D.
Dr. Otello Stampacchia, Ph.D.
Independent Director
Independent Director
--
-100.00%

FAQs

Who are the top five shareholders of ImageneBio Ord Shs?

The top five shareholders of ImageneBio Ord Shs are: Dr. Kristin Yarema, Ph.D.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.